SLFN11 has been highlighted as a potential marker for cancer cell chemosensitivity in platinum-based drugs [40], topoisomerase inhibitors [41,42,43,44,45], poly-ADP ribose inhibitors [46,47,48,49,50,51], and antibody-drug conjugates [45] in over ten cancer types [11]. This evidence concerns the gene SLFN11 and cancer.